Christopher Bunker
Vice President, Biopharma Business Development Alamar Biosciences Inc.
Seminars
Thursday 5th February 2026
NULISA Neurology Biomarker Platform – Brain-derived pTau217 & High-plex Neurodegenerative Disease & Neuroinflammatory Biomarker Analysis
9:30 am
- NULISA™: Ultra-sensitive femtogram level detection with barcode-based high-plex biomarker analysis
- First brain-derived (BD) pTau217 assay for highest accuracy blood-based Alzheimer's detection
- CNS Disease Panel: Unique in its coverage of hundreds of proteins involved in neurodegeneration, inflammation, vascular and synaptic dysfunction New BD-Tau181,217, 231, total assays
- Inflammation Panel: Comprehensive coverage of cytokines and key immune markers underlying neuroinflammatory disease
- NULISA platform: Unmatched ability to translate targeted neuroimmune proteomic discoveries into low-plex quantitative assays on the same ARGO HT System
- ARGO HT System: Fully automated instrument for running single-, low-, and high-plex assays
- NULISA IVD and ARGO DX in development with funding from Gates Ventures and DxA
